CTSO — Cytosorbents Corporation

Summary of CTSO Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Full Year 2025 Revenue: $37.1 million, up 4% year-over-year; flat on a constant currency basis.
• Q4 2025 Revenue: $9.2 million, a 1% increase year-over-year but down 8% on a constant currency basis.
• Gross Margin: 71% for the full year, improved to 74% in Q4, reflecting manufacturing efficiencies.
• Operating Loss: Full year loss improved to $14.7 million from $16.5 million in 2024; Q4 loss was $4.6 million compared to $3.7 million in Q4 2024.
• Net Loss: Q4 net loss of $5.5 million ($0.09 per share), improved from $7.6 million ($0.14 per share) in the prior year.
• Cash Position: $7.8 million at year-end, down from $9.1 million at the end of Q3 2025, with a net operating cash burn of $3.8 million in Q4.

2. Strategic Updates and Business Highlights

• Sales Growth: International sales outside Germany increased 13% to $8.6 million; distributor sales grew 11.4% to $16.5 million, comprising 68% of total revenue.
• Germany Restructuring: A proactive restructuring strategy is underway to improve sales performance, with early signs of improvement noted in Q1 2026.
• PuriFi Initiative: Over 100 units placed globally to expand access to CytoSorb therapy, with expectations for increased disposable usage and adherence to treatment protocols.
• DrugSorb-ATR Progress: FDA discussions ongoing for a resubmission after initial denial; recent clinical data supports the safety and efficacy of the product.

3. Forward Guidance and Outlook

• Cash Flow Breakeven: Management expects to achieve operating cash flow breakeven in the second half of 2026, supported by cost reductions and improved operational efficiencies.
• Revenue Growth Focus: Continued emphasis on driving consistent revenue growth, executing the turnaround in Germany, and advancing DrugSorb-ATR towards FDA approval.

4. Bad News, Challenges, or Points of Concern

• Decline in Germany Sales: Sales in Germany fell 10% to $11.8 million, attributed to restructuring efforts, indicating short-term challenges in this key market.
• Increased Operating Expenses: Q4 operating expenses rose to $11.4 million, including a $500,000 restructuring charge, which may impact profitability in the near term.
• Regulatory Risks: The previous denial from the FDA for DrugSorb-ATR raises concerns about the upcoming resubmission and the need for careful alignment with FDA expectations.

5. Notable Q&A Insights

• FDA Submission Timeline: Management is focused on ensuring alignment with the FDA before resubmitting DrugSorb-ATR, prioritizing clarity over speed to avoid another denial.
• Improvement in Germany: Early signs of improvement in the German market were discussed, with a focus on methodical sales development rather than opportunistic sales.
• PuriFi Revenue Model: The PuriFi pump is seen as a long-term investment strategy, similar to a printer-cartridge model, where initial costs are subsidized for future disposable revenue.

Overall, while CytoSorbents has made progress in various strategic initiatives and is optimistic about future growth, it faces challenges in Germany and regulatory hurdles that need to be navigated carefully.